Health Care Distributors

TIBET PHARMA

TIBET PHARMA released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 723.55 M, actual EPS CNY 0.93

Tibet Pharma FY2026 Q1 Earnings Release on April 29 After-Market (BJT)

TIBET PHARMA released FY2025 Q4 earnings on March 12 After-Market (BJT), actual revenue CNY 892.27 M, actual EPS CNY 0.67

TIBET PHARMA released FY2025 earnings on March 12 After-Market (BJT), actual revenue CNY 2.982 B (forecast CNY 4.07 B), actual EPS CNY 2.91 (forecast CNY 3.77)

TIBET PHARMA to release FY2025 earnings on March 13 After-Market BJT, forecast revenue CNY 4.07 B, EPS CNY 3.77

TIBET PHARMA released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 438.57 M, actual EPS CNY 0.4797

TIBET PHARMA released FY2025 9 Months Earnings on October 30 After-Market (BJT), actual revenue CNY 2.089 B, actual EPS CNY 2.2392

TIBET PHARMA to Release FY2025 Q3 Earnings on October 31 After-Market (BJT)

TIBET PHARMA released FY2025 Q2 earnings on August 15 During-Market BJT, actual revenue CNY 938.6 M, actual EPS CNY 0.9195

TIBET PHARMA released FY2025 Semi-Annual Earnings on August 15 During-Market (BJT), Actual Revenue: CNY 1.651 B, Actual EPS: CNY 1.76

Tibet Pharma to Release FY2025 Semi-Annual Earnings on August 16, 2025 (BJT)

Zangxiang Pharmaceutical Responds to Full Capacity Production Inquiry

Tibet Pharmaceutical's Subsidiary Obtains Approval for New Product Line

Tibet Pharmaceutical Announces Q1 2025 Earnings Report

TIBET PHARMA released FY2025 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 712.11 M, actual EPS CNY 0.84

TIBET PHARMA to Release FY2025 Q1 Earnings on April 29 After-Market BJT

TIBET PHARMA released FY2024 earnings on March 14 After-Market (BJT), actual revenue 2.807 B CNY (forecast 3.438 B CNY), actual EPS 3.26 CNY (forecast 3.18 CNY)

Tibet Pharma released FY2024 Q4 earnings on March 14 After-Market (BJT), actual revenue 631.27 M CNY, actual EPS 0.8001 CNY

TIBET PHARMA to Release FY2024 Earnings on March 15 After-Market (BJT), Forecast Revenue 3.438 B CNY, EPS 3.18 CNY

Tibet Pharmaceutical's Sales Show No Significant Seasonal Differences, Future Sales of Traditional Chinese Medicine Products Expected to Increase

Ordinary dividend (cash)

Ex Date: 2026.05.22, Cash dividend 0.876 CNY

600211

00867

On September 30th, Ruizheng Gene Co., Ltd. announced the completion of a Series A financing totaling USD 75 million and initiated a comprehensive strategic cooperation with the Series A investors TIBET PHARMA and CMS

Zhitong

Ruizheng Gene completed a $75 million Series A financing, initiating a comprehensive strategic partnership with TIBET PHARMA and CMS

601089

688166

Innovative drug concept stocks continue to decline, BrightGene fell over 8%, TIBET PHARMA fell over 7%, Foyou Pharma, Zhendong Pharmaceutical, and Maiwei Biotech all dropped

Foyou Pharma

BrightGene

Innovative drug concept stocks continue to decline, BrightGene falls over 8%

Tibet Nordicon Pharmaceutical Co., Ltd. provides a guarantee of 160 million yuan for its wholly-owned subsidiary to support its application for comprehensive credit from the bank. The guarantee has completed the approval process, and the current guarantee balance is 378.8029 million yuan, accounting for 18.44% of net assets. The company stated that the creditworthiness and debt repayment ability of the guaranteed party are good, and the overall risk is controllable

TIBET PHARMA provides a guarantee of 160 million for its subsidiary, with overall risks being controllable

According to the Zhitong Finance APP, TIBET PHARMA disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 1.651 billion yuan, a year-on-year increase of 2.23%; the net profit attributable to shareholders of the listed company was 567 million yuan, a year-on-year decrease of 8.96%; the net profit after deducting non-recurring gains and losses was 543 million yuan, a year-on-year increase of 3.69%; the basic earnings per share were 1.76 yuan. The company plans to distribute a cash dividend of 8.81 yuan (tax included) for every 10 shares to all shareholders

TIBET PHARMA released its semi-annual performance report, with a net profit attributable to the parent company of 567 million yuan, a year-on-year decrease of 8.96%

According to the Zhitong Finance APP, TIBET PHARMA disclosed its first-quarter report for 2025. During the reporting period, the company achieved revenue of 712 million yuan, a year-on-year increase of 1.12%; the net profit attributable to the parent company was 269 million yuan, a year-on-year decrease of 13.95%; the net profit excluding non-recurring gains and losses was 253 million yuan, a year-on-year increase of 7.90%. The basic earnings per share were 0.84 yuan

TIBET PHARMA released its first-quarter performance, with a net profit attributable to the parent company of 269 million yuan, a year-on-year decrease of 13.95%

According to the announcement from Zhitong Finance APP, TIBET PHARMA will implement the annual equity distribution for 2024, distributing a cash dividend of 0.728 yuan per share (including tax), with the equity registration date set for April 21

TIBET PHARMA will distribute a dividend of CNY 0.728 per share for the year 2024, with the record date for shareholders being April 21

TIBET PHARMA released its 2024 annual report, with revenue of 2.807 billion yuan, a year-on-year decrease of 10.45%; net profit attributable to shareholders of 1.051 billion yuan, a year-on-year increase of 31.26%; net profit excluding non-recurring items of 859 million yuan, a year-on-year increase of 9.45%; basic earnings per share of 3.26 yuan. The company plans to distribute a cash dividend of 7.28 yuan for every 10 shares to shareholders. The decline in revenue is mainly due to a decrease in sales of new active ingredients, leading to a drop in sales revenue. During the reporting period, the company received industrial support funds of 213.7486 million yuan

TIBET PHARMA released its 2024 annual performance, with a net profit attributable to the parent company of 1.051 billion yuan, a year-on-year increase of 31.26%

According to the Zhitong Finance APP, TIBET PHARMA announced that the company plans to distribute a cash dividend of RMB 0.262 per share (including tax) for the third quarter of 2024, with the equity registration date set for January 20, 2025, and the ex-dividend date set for January 21, 2025

In the third quarter, TIBET PHARMA plans to distribute a dividend of CNY 0.262 per share, with the ex-dividend date set for January 21

According to the Zhitong Finance APP, TIBET PHARMA announced that the profit distribution plan for the third quarter of 2024 is: a cash dividend of 2.62 yuan (including tax) for every 10 A shares

TIBET PHARMA's third-quarter profit distribution plan: a dividend of 2.62 yuan for every 10 shares

TIBET PHARMA(600211.SH)